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Abstract
Background: People from South Asia are at increased risk of type 2 diabetes (T2D). There is an urgent need to
develop approaches for the prevention of T2D in South Asians that are cost-effective, generalisable and scalable
across settings.
Hypothesis: Compared to usual care, the risk of T2D can be reduced amongst South Asians with central obesity or
raised HbA1c, through a 12-month lifestyle modification programme delivered by community health workers.
Design: Cluster randomised clinical trial (1:1 allocation to intervention or usual care), carried out in India, Pakistan,
Sri Lanka and the UK, with 30 sites per country (120 sites total). Target recruitment 3600 (30 participants per site)
with annual follow-up for 3 years.
Entry criteria: South Asian, men or women, age 40–70 years with (i) central obesity (waist circumference ≥ 100 cm
in India and Pakistan; ≥90 cm in Sri Lanka) and/or (ii) prediabetes (HbA1c 6.0–6.4% inclusive). Exclusion criteria:
known type 1 or 2 diabetes, normal or underweight (body mass index < 22 kg/m2); pregnant or planning
pregnancy; unstable residence or planning to leave the area; and serious illness.
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Endpoints: The primary endpoint is new-onset T2D at 3 years, defined as (i) HbA1c ≥ 6.5% or (ii) physician
diagnosis and on treatment for T2D. Secondary endpoints at 1 and 3 years are the following: (i) physical measures:
waist circumference, weight and blood pressure; (ii) lifestyle measures: smoking status, alcohol intake, physical
activity and dietary intake; (iii) biochemical measures: fasting glucose, insulin and lipids (total and HDL cholesterol,
triglycerides); and (iv) treatment compliance.
Intervention: Lifestyle intervention (60 sites) or usual care (60 sites). Lifestyle intervention was delivered by a
trained community health worker over 12 months (5 one-one sessions, 4 group sessions, 13 telephone sessions)
with the goal of the participants achieving a 7% reduction in body mass index and a 10-cm reduction in waist
circumference through (i) improved diet and (ii) increased physical activity. Usual care comprised a single 30-min
session of lifestyle modification advice from the community health worker.
Results: We screened 33,212 people for inclusion into the study. We identified 10,930 people who met study entry
criteria, amongst whom 3682 agreed to take part in the intervention. Study participants are 49.2% female and aged
52.8 (SD 8.2) years. Clinical characteristics are well balanced between intervention and usual care sites. More than
90% of follow-up visits are scheduled to be complete in December 2020. Based on the follow-up to end 2019, the
observed incidence of T2D in the study population is in line with expectations (6.1% per annum).
Conclusion: The iHealth-T2D study will advance understanding of strategies for the prevention of diabetes
amongst South Asians, use approaches for screening and intervention that are adapted for low-resource settings.
Our study will thus inform the implementation of strategies for improving the health and well-being of this major
global ethnic group.
IRB approval: 16/WM/0171
Trial registration: EudraCT 2016-001350-18. Registered on 14 April 2016. ClinicalTrials.gov NCT02949739. Registered
on 31 October 2016, First posted on 31/10/2016.
Background
South Asians, who represent one-quarter of the world’s
population, are at high risk of type 2 diabetes (T2D) [1].
India alone has ~ 77 million people with T2D, the sec-
ond highest number in the world [2]. T2D prevalence is
currently ~ 5% in rural India and ~ 11% in urban India
[3]. Similar patterns are observed amongst South Asians
in Pakistan, Bangladesh and Sri Lanka [4]. The adverse
consequences of diabetes are further magnified by the
earlier age of onset of T2D and by the low availability
and financial barriers to obtaining high-quality care in
South Asia [5]. South Asians living in Europe have a 2–4
times higher risk of T2D compared to Europeans, for
reasons that remain to be determined [5,6]. The high
burden of T2D in South Asians thus represents a major
public health challenge.
T2D is a preventable disorder. Amongst overweight
and obese Europeans with impaired glucose tolerance, a
programme of intensive lifestyle modification (increased
physical activity, dietary change and weight loss) is asso-
ciated with an ~ 60% relative risk reduction in the inci-
dence of T2D [7]. The benefits are maintained for at
least 10 years after the intervention has stopped [8].
Meta-analysis of published studies supports the potential
for lifestyle intervention to reduce the risk of T2D
amongst South Asians [9]. However, completed studies
have been predominantly carried out in urban settings,
and with under-representation of women, limiting the
generalisability of findings. Furthermore, the trials have
typically relied on the identification of high-risk individ-
uals using the oral glucose tolerance test and on delivery
of the lifestyle modification by trained healthcare teams,
approaches that are resource intensive and difficult to
scale up. As a result, interventions for the prevention of
T2D are not routinely available to South Asian commu-
nities, especially in LMIC settings.
Delivery of health promotion for the prevention of
chronic disease has traditionally been the responsibility
of physicians and allied health professionals. However,
recent research supports the view that community health
workers (CHWs) can make an effective contribution to
the prevention and early diagnosis of chronic disease
and deliver improved outcomes compared to usual care
[10]. Studies in rural India show that CHWs can provide
health education and support management of hyperten-
sive individuals [11]. A comprehensive multicomponent
intervention in Bangladesh, Pakistan and Sri Lanka
showed that trained CHWs working in partnership with
public healthcare systems improved blood pressure con-
trol amongst adults with hypertension [12]. Whether
CHWs can deliver lifestyle modification for prevention
of T2D in South Asians that is effective, cost-effective
and potentially scalable remains to be determined.
We therefore established the iHealth-T2D study, as a
large-scale cluster randomised clinical trial, to test the
hypothesis that the risk of T2D can be reduced amongst
Kasturiratne et al. Trials          (2021) 22:928 Page 2 of 13
South Asians with central obesity or raised HbA1c,
through a 12-month lifestyle modification programme
delivered by CHWs.
Preparatory work
Development of a lifestyle intervention programme for
delivery by CHWs
Our intervention programme was developed by a team
with expertise in nutrition, dietetics, epidemiology and
public health from the study centres in South Asia and
the UK and informed by the design of the Diabetes Pre-
vention Programme [7]. The primary objective was to
achieve a 7% reduction in body mass index and a 10-cm
reduction in waist circumference through (i) improved
diet and (ii) increased physical activity. Improved diet
comparised a 500-kcal energy reduction in energy intake
for the overweight and obese. The profile of the diet was
based on health eating guidelines, which are common
across non-communicable disease prevention pro-
grammes, and included attention to increasing fruit and
vegetable consumption, decreasing sugar intake, redu-
cing alcohol consumption (where appropriate) and por-
tion sizes, and identifying cooking substitutions to
reduce fat. Increased physical activity includes finding
enjoyable physical activities to pursue regularly and in-
corporating physical activity into daily routines. The tar-
get was to achieve 150 min of moderate physical activity
every week.
Core design elements of the programme included (1)
goal-based behavioural intervention, with goals set in
partnership with the individual on an ongoing basis; (2)
personalised support for the participant during delivery
of the intervention; (3) frequent contact to help partici-
pants achieve and maintain the weight and physical ac-
tivity goals; and (4) “Toolbox” strategies to tailor the
intervention to the individual participant. Components
specific to the current effort included (1) use of CHWs,
supported by local experts for delivery of lifestyle inter-
vention; (2) cultural adaptation included the develop-
ment of meal plans and behaviour change advice
suitable for South Asian communities; (3) incorporating
a family-based approach to the intervention, intervention
where one member of the patients family attended the
education sessions, given the evidence for improved re-
sponse to lifestyle advice when family members are in-
cluded in the education [13,14]; and (4) making use of
telephone and group sessions to bring peer support, to
improve accessibility of the intervention and to maxi-
mise the efficiency of delivery. Relevant stakeholders
(potential participants, CHWs and other healthcare pro-
viders) were involved in the design and adaptation
process.
The final lifestyle modification programme comprised
22 contact sessions over 12 months. The 22 sessions
comprised five one-one meetings (duration up to 60
min), four group sessions (up to 90min) and 13 tele-
phone sessions (up to 15 min). The use of group and
telephone contact sessions may improve participation,
engagement and outcomes of intervention programmes
compared to wholly face-face strategies [15–17]. Session
content and timing are summarised in Table 1 and in
the Supplementary Online Materials. The intervention
programme was supported by written materials for par-
ticipants, translated into local languages. This participant
Handbook contained educational information about the
importance of obesity and diabetes, the potential benefits
of lifestyle modification, and the key components of a
healthy lifestyle (focused on improved and increased
physical activity). The aim of the Handbook was to guide
participants through the lifestyle modification sessions
and support self-monitoring of their lifestyle behaviours,
goal setting, goal review and waist circumference.
Identification and training of CHWs
CHWs were graduates with a biological science back-
ground and were recruited from amongst the local com-
munity in which they worked, to ensure natural cultural
awareness. Training of CHWs was provided by local ex-
perts in diabetes, nutrition and exercise, according to
the principles and practices described in the intervention
protocols. Training covered theoretical knowledge as
well as practical hands-on learning in communication
and delivery of the intervention and lasted 2–3 weeks.
The study handbook summarised the protocols to be
followed and provided toolkits for promoting a healthy
diet and physical activity. All trainee CHWs were
assessed for knowledge, skills and attitude by the trainers
prior to commencing intervention. Each CHW was ex-
pected to initiate an intervention for 80–100 new partic-
ipants per year, followed by delivery of the complete
programme over the 12months.
Identification of South Asians at increased risk of diabetes
The glucose tolerance test has been the mainstay for the
identification of future risk for T2D. However, this is a
resource-intensive approach that is not well-suited for
implementation at a population scale. To address this
limitation, we used our longitudinal studies of South
Asian populations to identify non-laboratory and labora-
tory markers of risk that may be better suited to the
identification of susceptible individuals from the general
population. We compared a range of clinically relevant,
routinely available measures for prediction of new-onset
T2D, amongst the 17,000 South Asian men and women
aged 35 to 75 years, under long-term follow-up in the
London Life Science Prospective Population (LOLIPOP)
study [6]. Our results show that waist circumference is a
strong predictor of incident T2D in South Asians, which
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offers better discrimination than body mass index or
waist-hip ratio (Table 2). Waist circumference is a sim-
ple, readily available clinical measure of adiposity that is
well-suited for use as a tool for community-wide risk
stratification, especially in low-middle-income countries.
Our results also identify HbA1c as a highly predictive
biochemical tool for the identification of high-risk South
Asians [6] that achieves similar discrimination for T2D
to fasting glucose (Table 2). HbA1c has the additional
advantage of being a non-fasting assay, which is simpler
and cheaper to administer than an oral glucose tolerance
test. HbA1c is potentially well-suited for community-
wide and opportunistic screening. These observations
provide the rationale to investigate the clinical utility of
HbA1c and waist circumference for the identification of
South Asians at high risk of T2D, in the present study.
Methods
Study design
iHealth-T2D is a multi-centre, cluster randomised clin-
ical trial to evaluate intensive lifestyle modification deliv-
ered by CHWs for prevention of T2D, compared to
Table 1 Timetable for the lifestyle intervention programme delivered by the community health workers. Overall, there were four

















1 1 121 60 X X X X X
2 2 Phone 15 X
3 3 121 60 X X X X
4 5 Phone 15 X
5 7 Group 90 X X X
6 9 Phone 15 X
7 11 Group 90 X X X
8 13 Phone 15 X
9 15 Group 90 X X X
10 17 Phone 15 X
11 19 121 60 X X X X X
12 21 Phone 15 X
13 23 Phone 15 X
14 25 Group 90 X X X
15 28 Phone 15 X
16 31 Phone 15 X
17 34 Phone 15 X
18 37 Group 90 X X X
19 40 Phone 15 X
20 43 Phone 15 X
21 46 Phone 15 X
22 49 121 60 X X X X
Table 2 Risk factors for incident T2D (5 years) amongst South Asians in the LOLIPOP study [6]
Risk factor Prevalence T2D incidence Sensitivity RR for T2D
Biochemical
Fasting glucose ≥ 6.0 mmol/L (WHO) 5.0% 55.6% 19.3% 6.66 (4.89–9.07)
HbA1c ≥ 6.0% (WHO) 16.3% 68.4% 35.0% 13.9 (10.4–18.6)
Anthropometric
Body mass index > 28 kg/m2 (WHO) 17.0% 30.1% 32.6% 2.35 (1.96–2.82)
Waist-hip ratio (M > 1.0, F > 0.9) 28.0% 27.1% 46.2% 2.21 (1.88–2.60)
Waist: M or F ≥ 100 cm 28.9% 31.3% 49.6% 2.56 (2.21–3.06)
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usual care. Study entry criteria were South Asian, men
or women, age 40–70 years with (i) central obesity (waist
circumference ≥ 100 cm in India and Pakistan; ≥90 cm
in Sri Lanka) and/or (ii) prediabetes (HbA1c 6.0–6.4%
inclusive). Exclusion criteria were known type 1 or 2 dia-
betes, normal or underweight (body mass index < 22 kg/
m2); pregnant or planning pregnancy; unstable residence
or planning to leave the area; and serious illness. We
aimed to recruit 3600 participants from 120 locations
across 4 countries (India, Pakistan, Sri Lanka and the
UK) comprising 900 participants and 30 sites per coun-
try. Participants were cluster randomised based on study
site to receive either intensive lifestyle modification (N =
60 sites) or usual care (N = 60 sites). Participants will be
followed at 12, 24 and 36months after enrolment. The
primary endpoint is the incidence of T2D at 3 years.
The study was approved by an Institutional Review
Board (IRB) in each participating country (ref 16/WM/
0171) and was registered on the EudraCT database
(2016-001350-18). Primary funding for the study was
from the European Commission (award 643774). Imper-
ial College London acted as the sponsor for the study.
The complete study protocol and study materials are
available on our website: www.ihealth-t2d.org.
Study locations
Participants were recruited from 120 sites divided
equally between India, Pakistan, Sri Lanka and the UK
(i.e. 30 recruitment sites per country). On the Indian
subcontinent, study sites were distributed across a range
of socio-economic and geographic settings, to increase
the generalisability of the findings. Locations were iden-
tified based on the knowledge and advice of local experts
and available administrative data for the region. In the
UK, the study sites comprised GP surgeries in West
London (London boroughs of Ealing, Harrow and
Hounslow), selected as those serving populations with a
high proportion of South Asians.
In India, our 30 study sites were distributed around
five regional hubs comprising New Delhi (Delhi) and cit-
ies in four North Indian states: Gurugram (Haryana),
Vaishali (Ghaziabad, Uttar Pradesh), Mohali (Punjab)
and Muzaffarpur (Bihar). Delhi, officially known as the
National Capital Territory (NCT), is a city and a union
territory of India which includes New Delhi, the capital
of India. There were six study sites (three rural and three
urban or semi-urban) for each regional hub.
In Pakistan, the study area was the metropolitan dis-
trict of Lahore, the second most populous city of
Pakistan. It has an estimated population of approx.10
million with an urban:rural population in a 2:1 ratio.
The city is divided into 10 basic administrative divisions
(towns) that are further divided into smaller units
termed as Union Councils (urban) and Mouzas (rural/
village). Our 30 sites represented all 10 towns with an
average of 3 sites per town. The boundaries of each site
were based on the respective Union Council/Mouzas de-
fined by the main roads encompassing the area. There
were 20 urban and 10 rural sites. The urban sites were
congested, thus smaller and represented one union
council. Rural sites had less population density and thus
were large and represented 2 or more Mouzas or vil-
lages. The 30 study sites were co-ordinated through
three hubs: Services Institute of Medical Sciences
(SIMS), Punjab Institute of Cardiology (PIC) and Sharif
Hospital.
In Sri Lanka, the study was conducted in Colombo
and Gampaha districts, the two most urban and
populous districts of the country. Colombo district has
13 administrative divisions. We selected two of these di-
visions, each representing predominantly urban and pre-
dominantly rural populations. Eight (n = 8) clusters were
selected from the urban setting and seven clusters were
selected from the rural setting. A cluster was defined as
a Grama Niladhari division. Gampaha district has 13
administrative divisions. Only seven of these divisions
have urban populations. We sampled one urban cluster
(n = 7) from each of the divisions with urban popula-
tions. One cluster each was selected from the other six
divisions with only rural populations (n = 6). Two add-
itional rural clusters were selected from the two most
populous divisions that have both urban and rural popu-
lations (n = 2). A cluster was defined as a Grama Nilad-
hari division with a Primary Care Hospital (Primary
Medical Care Unit/Divisional Hospital) or a Maternal
and Child Health clinic where screening can be
conducted.
The 120 research sites were cluster randomised to
intervention or usual care (1:1 allocation). Randomisa-
tion was done by the project management team at Im-
perial College London, using computer-generated
random numbers, and as stratified by country to ensure
15 intervention and 15 usual care sites per country. Ran-
domisation was carried out before recruitment started.
Recruitment to the study
We invited South Asian men and women aged 40–70
years and without known diabetes to be considered for
the study. Recruitment was a two-stage process: (i) an
initial screening visit to assess eligibility for the interven-
tion trial; (ii) an enrolment visit, to confirm eligibility
and to obtain consent for inclusion in the intervention
phase of the trial.
In South Asia, our primary recruitment strategy com-
prised an open invitation to individuals living in the
community at study sites, to attend for an iHealth-T2D
Screening visit. We first discussed the study with the
relevant administrative and health authorities to engage
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their support and permission to operate. We held dis-
cussions with community leaders and open meetings to
identify suitable approaches for engaging local commu-
nities in the project. We distributed knowledge of the
project and invited people to attend for screening
through trusted sources of health information (e.g.
health centres, physicians and healthcare providers, grass
root level non-physician health workers, accredited so-
cial health activists and volunteer groups). People were
encouraged to discuss the project with neighbours and
friends to help widen engagement. The screening health
assessment was held in local community health centres
easily accessible to the target community.
In the UK, our primary strategy was postal invitation.
We sent letters by post, to men and women aged 40–70
years, registered to the practice lists of collaborating
general practitioners and who were recorded to be of
South Asian ethnicity, and not known to have diabetes.
We sent 14,564 invitations, from which 3031 attended a
screening visit (22%). From these, 408 attended enrol-
ment and 240 were recruited to trial (i.e. 1.6% of people
invited were ultimately recruited to the intervention
phase). Screening was carried out in local GP surgeries,
and subsequent visits at a dedicated research clinic based
at Ealing Hospital. As a secondary strategy in the UK,
we also took advantage of a database comprising the re-
sults of cardiovascular health assessments recently car-
ried out amongst 9699 South Asians in the study sites,
as part of the LOLIPOP study (2010–2015). These base-
line assessments were done using methods identical to
those of the iHealth-T2D Screening visit and are thus
directly comparable. This approach enabled identifica-
tion of South Asians meeting the study entry criteria
based on HbA1c or waist circumference, who were then
invited directly to a study enrolment visit using a single
letter of invitation (2872 invitations sent; 1026 attended;
36% response rate). From these, 579 were recruited to
trial (i.e. 20.2% of people invited). This secondary strat-
egy also enables the evaluation of the cost-effectiveness
for recruitment to lifestyle intervention based on exist-
ing, routinely collected healthcare data, compared to
using systematic population-based screening strategies.
Screening and enrolment visits
Potential participants were invited to attend an initial
screening visit to assess them for eligibility (Table 3).
This comprised (i) questionnaire (socio-demographic de-
tails, medical and drug history with emphasis on dia-
betes and cardiovascular disease, smoking and alcohol
consumption), (ii) physical measurements (waist circum-
ference, height, weight and blood pressure) and (iii) fast-
ing blood samples (overnight) for measurement of
HbA1c (study entry criterion), and for storage to enable
epidemiological research into biomarkers for metabolic
and cardiovascular health. Data collection forms are
available on the study website (www.iHealth-T2D.org),
and study methods in the protocol. People reaching the
study entry criteria based on the initial screening assess-
ment were invited to attend for an enrolment visit. The
data collected at enrolment is the baseline data against
which subsequent health outcomes will be assessed. In
addition to repeating the measures collected in the
screening visit, participants also completed the Global
Physical Activity Questionnaire (GPAQ) and Health-
related quality of life questionnaire (EQ-5D-5L). South
Asians who continued to meet the study eligibility
Table 3 Schedule visits for the iHealth-T2D study. GPAQ generalised physical activity questionnaire, Quality of life EQ-5D-5L
Screening Enrolment Follow-up 1 Follow-up 2 Follow-up 3
Time −30 days 0 12 months 24 months 36months
Consent X X
Demographics X
Alcohol intake X X X X X
Tobacco intake X X X X X
Medications X X X X X
Medical history X X X X X
EQ-5D-5L X X X X
GPAQ X X X X
24-h food diary X X X X
Height X
Weight, waist, hip X X X X X
Blood pressure X X X X X
HbA1c X X X X X
Biological samples X X X X X
Kasturiratne et al. Trials          (2021) 22:928 Page 6 of 13
criteria were invited to enrol into the intervention phase
of the study (Fig. 1).
All measures were carried out according to standar-
dised protocols. Waist circumference was measured at
the midpoint between the lower margin of the ribs and
the top of the iliac crest. Hip circumference was mea-
sured at the level of the greater trochanters. Waist and
hip measurements were measured three times and the
average calculated. Weight was measured in light cloth-
ing using portable digital scales accurate to 0.1 kg, and
height using a portable stadiometer. Blood pressure was
measured in the seated position using Omron digital de-
vices. Three measurements were obtained from each
participant, 1 min apart. All people attending for a study
visit were given a printed report of their results, along
with written guidance on their interpretation. HbA1c
was measured using Biorad D10 or Variant II turbo as-
says. Assays were performed in local laboratories that
participate in external quality control, and meet the
standards of the International Federation of Clinical
Chemists. All participants with newly detected medical
conditions were referred to the local health service.
Fig. 1 Overview of recruitment to the study
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Study intervention
At the 60 study sites randomised to the intervention,
lifestyle modification was provided by the trained study
CHW to the index cases, over 12 months (22 contact
sessions), using the approaches set out in the study
protocol. Family members of the index case living in the
same household were encouraged to take part in lifestyle
modification. Participation of family members was
optional.
At the 60 study sites randomised to usual care, partici-
pants received a single episode of brief lifestyle interven-
tion for diabetes prevention, supported by written
material. This session lasted 30–60min and was deliv-
ered by the CHW.
Follow-up visits
All participants enrolled to the study were asked to at-
tend follow-up visits at 12, 24 and 36 months after re-
cruitment. Follow-up assessments were conducted by a
member of the research team, and not by the CHW pro-
viding the intervention. At each follow-up visit, study
participants completed a structured assessment similar
to the enrolment evaluation. This included (i) follow-up
questionnaire, (ii) physical measurements (waist circum-
ference, weight and blood pressure), (iii) GPAQ and EQ-
5D-5L and (iv) fasting venous blood sample for measure-
ment of HbA1c and serum biomarkers. Protocols and
equipment were identical to those used for the baseline
evaluation.
Blinding and data handling
As the trial involves active intervention on both arms, it
was not possible for participants and intervention staff
to be blinded. However, outcome assessors and data an-
alysts were kept blind to the allocation. The trial estab-
lished procedures to maintain separation between staff
that take outcome measurements and staff that deliver
the intervention. Staff members who obtained outcome
measurements were not directly informed of the group
assignment. Intervention staff and dieticians who deliv-
ered the intervention did not take outcome measure-
ments during follow-up. All investigators, staff and
participants were kept masked to outcome measure-
ments and trial results. Personal and research data were
collected by the local study team. Research data were
coded (de-identified) with removal of personal identi-
fiers, prior to sharing for analysis. The personal identi-
fiers were not shared outside the local investigator team.
The final trial dataset is accessible to the principal inves-
tigators at the partner institutions and their teams. It is
also available to other researchers on request to the
Study Steering Committee.
Study administration
The Steering Committee provided overall supervision of
trial conduct. Day-to-day management of the study was
co-ordinated through the Project Management Team,
based at Imperial College London working in partner-
ship with the project co-ordinators at each of the study
centres. The Project Management Team was responsible
for day-day administrative and scientific management of
the project, including study planning, organisation of
meetings, delivery of the annual reports, trial master files
and compliance. The trial was monthly reviewed for
study activity, data completeness and timeliness by the
Project Management Team. In addition, the Project
Management Team from Imperial College London vis-
ited study sites annually visited to audit trial conduct.
The funder was not involved in trial monitoring or audit.
Further details about the project are available on the
project website (www.ihealth-t2d.eu). Changes to study
protocol will be co-ordinated by the Project Manage-
ment Team at Imperial College and agreed by the study
Steering Committee. They will be submitted to the study
sponsor and the involved ethics committees for approval
prior to implementation and published on the trial regis-
try website (clinicaltrials.gov).
Dissemination
Results of the study will be submitted for publication
and reported at national and international meetings. Re-
sults will also be made available through the study web-
site. International Committee of Medical Journal Editors
(ICMJE) Recommendations will be followed for author-
ship eligibility. No professional writers will be involved.
Statistical code will be available through GitHub or
equivalent at publication. Study datasets are available
through application to the Steering Committee. After
the end of the research, an anonymised dataset will be
made publicly available.
Statistical analysis and data management
All analyses will be carried out according to our pub-
lished statistical analysis plan (SAP) [18]. Full details of
the statistical approach are described in the SAP and are
briefly summarised here.
Study endpoints
The primary endpoint is new-onset T2D in the index
case, defined as (i) HbA1c ≥ 6.5% or (ii) physician diag-
nosis and on treatment for T2D. Secondary endpoints
are the following: (i) physical measures: waist circumfer-
ence, weight and blood pressure; (ii) lifestyle measures:
smoking status, alcohol intake, physical activity and diet-
ary intake; (iii) biochemical measures: fasting glucose, in-
sulin and lipids (total and HDL cholesterol,
triglycerides); and (iv) treatment compliance. Any
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adverse events were reported to the local principal inves-
tigator. Serious adverse events were reported to the
study sponsor as well.
Sample size and power calculations
The study aimed to include 3600 participants. Assuming
that even rates for T2D for usual care are 6.8% per year,
the study has 81% power to identify at p < 0.05 a reduc-
tion in T2D incidence of 35%, after a follow-up period
of 3 years with an estimated drop-out rate of 10% within
the total population [9].
Data analysis
The primary analyses, conducted after 3 years of follow-
up, will investigate whether intensive lifestyle modifica-
tion reduces the risk of new-onset T2D (primary end-
point) compared to usual care amongst South Asians
with (i) central obesity (N ~ 2700 participants), (ii) raised
HbA1c (N ~ 900 participants) and (iii) overall (central
and/or prediabetes, all ~ 3600 participants). The analyses
will be performed according to the intention to treat
principle with data from all participants enrolled in the
study [19]. Multiple imputation will be used to address
missing data. Random effects logistic regression will be
used to estimate odds ratios for incidence of T2D and
95% CI. Secondary outcomes will be evaluated both after
1 and 3 years of follow-up, which will allow for compari-
sons of both short- and long-term effects of the lifestyle
intervention. Subgroup analyses amongst participants in-
cluded in the study based on HbA1c and/or waist cir-
cumference will be performed. The differences between
the two treatment arms will be estimated with a multi-
level linear mixed-effects regression model.
Health economic analysis
The primary aim of the health economic analysis is to
determine the cost-effectiveness of lifestyle modification
vs usual care for prevention of T2D amongst (i) South
Asians on the Indian subcontinent and (ii) South Asians
in Europe. The health economic analyses will include
pre-specified subgroup analyses of cost-effectiveness be-
tween (i) South Asians identified to be at high risk of
T2D based on central obesity vs raised HbA1c ≥ 6.0%;
(ii) low-middle-income (Indian subcontinent) vs high-
income (UK) regions; and (iii) socio-demographic: sex,
socio-economic classes and across ages. The results of
the cost-effectiveness analyses will be used to describe
the potential clinical and financial implications of imple-
menting the approaches into standard practice in the
local and national health economies. Effectiveness will
be expressed in quality-adjusted life years (QALYs),
using responses to the EQ-5D-5L, as well as T2D cases
prevented. Cost-effectiveness analyses will be performed
based on the follow-up period, estimating incremental
costs and QALYs using multi-level linear regression
models in line with statistical analysis of other study
endpoints, as well as using parametric extrapolation
techniques to evaluate the intervention over longer time
horizons. The estimates will enable assessment of the
scalability of an intensive lifestyle modification interven-
tion delivered by CHWs for the prevention of T2D,
using central obesity and/or HbA1c for screening. The
analyses of the costs of scaling-up will take into account
available and future resource envelopes in the South
Asian countries, and also current and future pricing for
assays such as HbA1c, to understand current and future
feasibility.
Results
Participants were recruited between 15/06/2016 and 05/
03/2019. Figure 1 shows the trial profile. In total, 33,212
people were screened for inclusion into the study. There
were 23,542 people who attended an iHealth-T2D
Screening Visit (Table 4). There were 10,930 people who
met study entry criteria after the screening visit and who
were invited to attend for the enrolment visit. Amongst
these, 5240 people attended, of whom 4261 people
(81.3%) continued to meet study inclusion criteria. The
primary reasons for participants not being eligible at the
enrolment assessment were waist circumference initially
raised, but below the threshold on repeat (N = 251);
HbA1c initially 6.0–6.4%, but < 6.0% on repeat (N =
375); repeat HbA1c ≥ 6.5% (N = 200) or now diagnosed
T2D (N = 42); repeat BMI < 22 kg/m2 (N = 34); and in-
complete data (N = 41).
Of these 4261 people meeting study entry criteria after
completion of the enrolment visit, 3682 (86.4%) agreed
to take part in the intervention phase (Table 5). There
were no differences in gender between those who agreed
or declined to take part in the intervention (agreed: male
86.6%, female 84.8%, P = 0.09). There were also no ma-
terial differences in age (53.6 ± 8.7 vs 55.0 ± 8.7 years),
body mass index (30.3 ± 4.5 vs 30.5 ± 4.9 kg/m2), waist
(104.0 ± 9.3 vs 103.0 ± 10.7 cm) or HbA1c (5.76 ± 0.43
vs 5.77 ± 0.47 %) amongst those who agreed to take part
in the intervention compared with those who declined,
respectively (all P > 0.05).
The 3682 study participants are 49.2% female and aged
52.8 (SD 8.2) years. Clinical characteristics are well bal-
anced between intervention and usual care sites (Table
6). The median number of participants recruited at each
study site is 30 (range 13–54). More than 90% of follow-
up visits are scheduled to be complete in December
2020. Based on the follow-up to end 2019, the observed
incidence of T2D in the study population is 6.1% per
annum. This compares favourably with the incidence
predicted in the study protocol and power calculation.
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Discussion
We describe the rationale, design and implementation of
the iHealth-T2D study, a cluster randomised trial that
sets out to determine whether lifestyle intervention de-
livered by community health workers, to South Asians
with central obesity or prediabetes, reduces the risk of
T2D over 3 years. Our study is notable for the large
sample size, multi-country design and the use of tools
for screening and intervention that have been adapted
for low-resource settings.
T2D is a major chronic disease, usually requiring life-
long pharmacological treatment. Having T2D substan-
tially increases a person’s risk of future myocardial
infarction, stroke, heart failure, visual impairment, renal
impairment, cancer and other long-term conditions [20].
T2D is thus a leading global cause of morbidity, mortal-
ity and healthcare expenditure. The burden of T2D is
especially high in South Asia [4–6]. The World Health
Organization, United Nations and the International Dia-
betes Federation all recognise that there is an urgent
need for action to reverse the current epidemic of T2D
in South Asians.
T2D is preventable by lifestyle intervention comprising
improved diet, weight loss and increased physical activity
[7,8]. Although many of the studies have been carried
out in European populations, lifestyle interventions have
been confirmed to reduce the risk of T2D in South
Asians [9]. However, the available literature suggests that
the benefits of lifestyle intervention may be lower in
South Asians. The reasons are not known but may in-
clude differences in disease aetiology, limited under-
standing or compliance with the intervention, reduced
availability of alternate healthy foods or facilities for
physical activity, social pressures that inhibit behaviour
Table 4 Characteristics of the 23,543 participants attending a screening visit
India Pakistan Sri Lanka UK
N 6913 6962 6535 3132
Female gender (%) 37.7% 47.6% 68.2% 53.1%
Age (years) 51.6 (8.8) 51.8 (8.6) 53.2 (8.7) 54.6 (8.8)
Current smoking (%) 6.2% 9.3% 7.3% 7.1%
Skilled worker (%) 58.0% 25.6% 28.3% 51.9%
Married (%) 96.2% 94.0% 84.8% 84.2%
Body mass index (kg/m2) 27.5 (4.6) 28.7 (5.7) 25.3 (4.4) 27.2 (4.5)
Systolic BP (mmHg) 133.8 (18.1) 130.4 (20.4) 134.2 (19.8) 127.8 (17.0)
Diastolic BP (mmHg) 81.9 (10.6) 80.8 (12.1) 78.6 (11.0) 79.3 (10.1)
Waist (cm) 98.1 (11.2) 97.9 (12.1) 87.8 (10.9) 93.1 (11.9)
Central obesity (%) 46.9% 43.9% 26.4% 27.1%
HbA1c (%) 6.1 (1.4) 6.3 (1.5) 6.0 (1.2) 5.6 (0.5)
Prediabetes (%) 19.2% 31.2% 23.5% 18.8%
HbA1c ≥ 6.5% (%) 21.8% 24.2% 14.4% 2.7%
Table 5 Characteristics of the 3682 participants starting intervention
India Pakistan Sri Lanka UK
N 909 1070 884 819
Female gender (%) 46.8% 48.5% 67.9% 32.5%
Age (years) 50.5 (8.0) 51.7 (7.8) 53.4 (7.8) 59.3 (8.5)
Current smoking (%) 4.1% 7.6% 5.2% 5.6%
Body mass index (kg/m2) 30.2 (4.2) 31.2 (5.2) 28.9 (3.9) 30.7 (4.2)
Systolic BP (mmHg) 131.4 (14.8) 127.9 (18.4) 131.2 (16.9) 135.7 (16.4)
Diastolic BP (mmHg) 81.3 (9.1) 81.9 (11.4) 79.6 (10.5) 82.3 (9.6)
Waist (cm) 105.5 (7.4) 105.1 (9.8) 97.9 (8.3) 107.0 (8.9)
Central obesity (%) 91.9% 78.5% 73.6% 88.0%
HbA1c (%) 5.6 (0.5) 5.9 (0.4) 5.8 (0.4) 5.7 (0.4)
Prediabetes (%) 32.9% 54.7% 56.6% 38.1%
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change, or the fidelity of implementation. The evidence
for heterogeneity of effect between populations demon-
strates the need for specific assessment of the clinical
and cost-effectiveness for diabetes interventions in South
Asian individuals from the varied ethnic and population
subgroups, and in diverse settings. Furthermore, the
evidence-based approaches currently described have not
been scaled up and are not routinely available in clinical
practice. Obstacles to sustainable implementation in-
clude reliance on the oral glucose tolerance test to iden-
tify high-risk individuals, as well as the use of dieticians
and other qualified healthcare workers for the delivery
of the intervention. The human and financial resources
needed for implementation of these established ap-
proaches have are major obstacles to deployment at
scale.
On this background, we designed the iHealth-T2D
study, with the overall goal of advancing the prevention
of T2D in South Asian populations. iHealth-T2D was
designed to build on previous work, address key limita-
tions in knowledge and explore more scalable ap-
proaches to the delivery of lifestyle intervention amongst
South Asians. Our study includes three key innovations
compared to previous work. First, we use waist circum-
ference and HbA1c for the identification of South Asians
at increased risk of T2D. Central obesity is widely recog-
nised to be a defining characteristic for susceptibility to
T2D amongst South Asians and can be assessed rapidly,
reproducibly and accurately, using low-technology, low-
cost approaches, by people with minimal training, and
without a qualified healthcare background. Waist cir-
cumference is ideally suited to resource-poor settings.
The choice of HbA1c was informed by our longitudinal
population data, which identifies HbA1c as a highly pre-
dictive marker of risk for future diabetes in South Asians
that can be rapidly measured using point of contact
devices, using a single blood test, and without the need
for fasting. Together, these characteristics make HbA1c
well-suited to population screening in low-resource set-
tings. Second, we use community health workers, com-
bined with group and telephone contacts, for the
delivery of the intervention with the goal of improving
the cost-effectiveness, scalability and sustainability of im-
plementation. Multiple studies from South Asia, and
other low-resource settings, support the view that com-
munity health workers can provide clinically effective
care for chronic diseases, such as hypertension and dia-
betes [10–12]. A role in diabetes prevention has not pre-
viously been evaluated. The results of the present study
are thus anticipated to inform ongoing task shifting in
primary healthcare systems, in support of improved pre-
vention and control for non-communicable disease. Fi-
nally, our study is notable for its multi-country design
and large sample size. This will enable investigation of
the effectiveness on the intervention in key population
subgroups, including different cultural, geographic and
socio-economic settings. Our results will thus substan-
tially extend knowledge for implementation and effect-
iveness for diabetes prevention in a range of contexts
relevant to South Asian communities.
Our study does also have some limitations. Our re-
cruitment methods did not enable the assessment of re-
sponse rates in South Asia, raising the possibility of
responder bias. However, the characteristics of partici-
pants are similar to those reported in other studies, ar-
guing against significant population stratification. Our
intervention still involves intervention by a health
worker, which may represent an obstacle to scale-up.
However, we implement task shifting from traditional
healthcare teams to community health workers, to pro-
mote cost-effectiveness and sustainability. We also note
that the intensive interventions using peer-support or
digital strategies for lifestyle modification have not
shown evidence for diabetes prevention in South Asians
[21,22]. Our experiment will thus add to the spectrum of
approaches to delivery and aims to deliver an optimal
combination of resource utilisation and clinical effective-
ness. We will not be able to collect individual-level
health expenditure data, which will limit the accuracy of
our health economic evaluation. We will mitigate against
this through the use of curated datasets that we have
created for health-related costs across South Asia.
In summary, the iHealth-T2D study of 3682 South
Asians with central obesity or prediabetes will determine
whether lifestyle modification delivered by community
health workers will reduce the risk of T2D over 3 years.
The iHealth-T2D study offers the opportunity to ad-
vance understanding of how best to prevent diabetes
amongst South Asians and thereby address a key public
health challenge in this major global ethnic group.
Table 6 Characteristics of participants in active and usual care
sites. P values are adjusted for differences in age, gender and
country
Active Usual care P
N 1844 1838
Age 53.3 (8.7) 53.7 (8.6) 0.18
Sex (female %) 52.1% 49.3% 0.09
Never smoked 86.2% 86.1% 0.97
Height 162.7 (9.7) 161.9 (9.7) 0.32
Weight 80.3 (13.7) 79.1 (13.5) 0.31
BMI 30.3 (4.5) 30.2 (4.6) 0.41
Waist 103.9 (9.3) 103.8 (9.4) 0.70
SBP 130.7 (16.9) 131.9 (17.1) 0.51
DBP 81.0 (10.2) 81.6 (10.4) 0.42
HbA1c 5.76 (0.43) 5.74 (0.43) 0.49
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